Login to Your Account

Investors unruffled as AB Science halts phase III RA study

By Cormac Sheridan
Staff Writer

Tuesday, September 22, 2015
DUBLIN – Shares in AB Science SA dipped just 4.7 percent Tuesday on news that it was halting a phase III trial of its tyrosine kinase inhibitor (TKI), masitinib, in rheumatoid arthritis (RA) following a futility analysis, which showed the study's probability of success was below 50 percent.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription